Funding of $37 Million in Series C secured for the progression of contemporary medication production through Phlow
Phlow, an American pharmaceutical contract development and manufacturing organization (CDMO), has raised $37 million in its Series C funding round. The funding, led by Align Private Capital, will be used to expand Phlow's U.S. development, manufacturing, and digital capabilities, with a strong focus on technology-driven innovations.
Phlow's CEO, Eric S. Edwards, MD, Ph.D., attributes the company's growth to collaborative efforts aimed at stabilizing the supply chain and ending chronic shortages of essential medicines and medical countermeasures for Americans. The investment will accelerate Phlow’s mission to innovate in pharmaceutical manufacturing by leveraging AI and advanced manufacturing systems to bring life-changing medicines to the market more efficiently and securely within the U.S.
The funding will primarily be directed towards scaling AI-driven technologies to improve efficiency in the production of Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs). It will also be used to implement next-generation manufacturing technologies, including advanced systems capable of both batch and continuous production processes.
Phlow will enhance its digital infrastructure to optimize pharmaceutical manufacturing and strengthen domestic pharmaceutical supply chains. The company is also focusing on supporting environmentally sustainable, cost-efficient manufacturing processes. These enhancements will help Phlow expand its CDMO services to improve cost efficiency and environmental sustainability.
Phlow has already made significant strides in this direction. It has launched two cGMP manufacturing facilities capable of kilogram to metric-ton scale API production. The company has also secured over $600 million in government contracts and shipped over 1.6 million vials of essential medicines to children's hospitals.
Align Private Capital, the lead investor in this round, expressed excitement about supporting Phlow's efforts to address inefficiencies in the U.S. pharmaceutical supply chain. Anna Nekoranec, CEO of Align Private Capital, applauded Phlow's initiatives to prevent pediatric drug shortages and advance technology-enabled API manufacturing.
The investment in Phlow demonstrates the confidence of both new and existing investors in the company's vision. Phlow's Chief Financial Officer, Dave Ryan, expressed excitement about the investment, stating that it will accelerate Phlow's ability to support small molecule API development and manufacturing programs for small and large clinical and commercial volumes.
Moreover, Align Private Capital supports Phlow's efforts to support the U.S. military. Phlow has partnered with the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense to develop medical countermeasures.
The most recent funding round for Phlow validates the company's vital mission. With this investment, Phlow is poised to make significant strides in improving the efficiency, sustainability, and security of the U.S. pharmaceutical supply chain.
Science and technology will play crucial roles in Phlow's expansion, as the funding will be used to scale AI-driven technologies and implement next-generation manufacturing technologies for more efficient pharmaceutical manufacturing, including continuous production processes. Health-and-wellness is significantly impacted, as the investment aims to prevent pediatric drug shortages and strengthen domestic pharmaceutical supply chains. Finance is also involved, with the $37 million Series C funding round led by Align Private Capital, demonstrating the confidence of investors in Phlow's vision for small molecule API development and manufacturing.
